This is a list of therapeutic, diagnostic and preventive monoclonal antibodies, antibodies which are clones of a single parent cell. When used as drugs, the International Nonproprietary Names (INNs) end in -mab. The remaining syllables of the INNs, as well as the column Source, are explained in Nomenclature of monoclonal antibodies.
The abbreviations in the column Type are as follows:
- mab: whole monoclonal antibody
- Fab: fragment, antigen-binding (one arm)
- F(ab')2: fragment, antigen-binding, including hinge region (both arms)
- Fab': fragment, antigen-binding, including hinge region (one arm)
- Variable fragments:
- scFv: single-chain variable fragment
- di-scFv: dimeric single-chain variable fragment
- sdAb: single-domain antibody
- Bispecific monoclonal antibodies:
- 3funct: trifunctional antibody
- BiTE: bi-specific T-cell engager
This list includes approved and investigational drugs as well as drugs that have been withdrawn from market; consequently, the column Use does not necessarily indicate clinical usage.
Name | Trade name | Type | Source | Target | Use |
---|---|---|---|---|---|
3F8 | mab | mouse | GD2 | neuroblastoma | |
8H9 | mab | mouse | B7-H3 | neuroblastoma, sarcoma, metastatic brain cancers | |
Abagovomab | mab | mouse | CA-125 (imitation) | ovarian cancer | |
Abciximab | ReoPro | Fab | chimeric | CD41 (integrin alpha-IIb) | platelet aggregation inhibitor |
Actoxumab | mab | human | Clostridium difficile | Clostridium difficile infection | |
Adalimumab | Humira | mab | human | TNF-α | Rheumatoid arthritis, Crohn's Disease, Plaque Psoriasis, Psoriatic Arthritis, Ankylosing Spondylitis, Juvenile Idiopathic Arthritis |
Adecatumumab | mab | human | EpCAM | prostate and breast cancer | |
Afelimomab | F(ab')2 | mouse | TNF-α | sepsis | |
Afutuzumab | mab | humanized | CD20 | lymphoma | |
Alacizumab pegol | F(ab')2 | humanized | VEGFR2 | cancer | |
ALD518 | ? | humanized | IL-6 | rheumatoid arthritis | |
Alemtuzumab | Campath, MabCampath | mab | humanized | CD52 | CLL, CTCL |
Alirocumab | mab | human | NARP-1 | hypercholesterolemia | |
Altumomab pentetate | Hybri-ceaker | mab | mouse | CEA | colorectal cancer (diagnosis) |
Amatuximab | mab | chimeric | MORAb-009 | cancer | |
Anatumomab mafenatox | Fab | mouse | TAG-72 | non-small cell lung carcinoma | |
Anrukinzumab (= IMA-638) | mab | humanized | IL-13 | ? | |
Apolizumab | mab | humanized | HLA-DR ? | hematological cancers | |
Arcitumomab | CEA-Scan | Fab' | mouse | CEA | gastrointestinal cancers (diagnosis) |
Aselizumab | mab | humanized | L-selectin (CD62L) | severely injured patients | |
Atinumab | mab | human | RTN4 | ? | |
Atlizumab (= tocilizumab) | Actemra, RoActemra | mab | humanized | IL-6 receptor | rheumatoid arthritis |
Atorolimumab | mab | human | Rhesus factor | hemolytic disease of the newborn | |
Bapineuzumab | mab | humanized | beta amyloid | Alzheimer's disease | |
Basiliximab | Simulect | mab | chimeric | CD25 (α chain of IL-2 receptor) | prevention of organ transplant rejections |
Bavituximab | mab | chimeric | phosphatidylserine | cancer, viral infections | |
Bectumomab | LymphoScan | Fab' | mouse | CD22 | non-Hodgkin's lymphoma (detection) |
Belimumab | Benlysta, LymphoStat-B | mab | human | BAFF | non-Hodgkin lymphoma etc. |
Benralizumab | mab | humanized | CD125 | asthma | |
Bertilimumab | mab | human | CCL11 (eotaxin-1) | severe allergic disorders | |
Besilesomab | Scintimun | mab | mouse | CEA-related antigen | inflammatory lesions and metastases (detection) |
Bevacizumab | Avastin | mab | humanized | VEGF-A | metastatic cancer |
Bezlotoxumab | mab | human | Clostridium difficile | Clostridium difficile infection | |
Biciromab | FibriScint | Fab' | mouse | fibrin II, beta chain | thromboembolism (diagnosis) |
Bimagrumab | mab | human | ACVR2B | myostatin inhibitor | |
Bivatuzumab mertansine | mab | humanized | CD44 v6 | squamous cell carcinoma | |
Blinatumomab | BiTE | mouse | CD19 | cancer | |
Blosozumab | mab | humanized | SOST | osteoporosis | |
Brentuximab vedotin | mab | chimeric | CD30 (TNFRSF8) | hematologic cancers | |
Briakinumab | mab | human | IL-12, IL-23 | psoriasis, rheumatoid arthritis, inflammatory bowel diseases, multiple sclerosis | |
Brodalumab | mab | human | IL-17 | inflammatory diseases | |
Canakinumab | Ilaris | mab | human | IL-1? | rheumatoid arthritis |
Cantuzumab mertansine | mab | humanized | mucin CanAg | colorectal cancer etc. | |
Cantuzumab ravtansine | mab | humanized | MUC1 | cancers | |
Caplacizumab | mab | humanized | VWF | ? | |
Capromab pendetide | Prostascint | mab | mouse | prostatic carcinoma cells | prostate cancer (detection) |
Carlumab | mab | human | CNTO888 | oncology/immune indications | |
Catumaxomab | Removab | 3funct | rat/mouse hybrid | EpCAM, CD3 | ovarian cancer, malignant ascites, gastric cancer |
CC49 | mab | mouse | TAG-72 | tumor detection | |
Cedelizumab | mab | humanized | CD4 | prevention of organ transplant rejections, treatment of autoimmune diseases | |
Certolizumab pegol | Cimzia | Fab' | humanized | TNF-α | Crohn's disease |
Cetuximab | Erbitux | mab | chimeric | EGFR | metastatic colorectal cancer and head and neck cancer |
Ch.14.18 | mab | chimeric | ??? | neuroblastoma | |
Citatuzumab bogatox | Fab | humanized | EpCAM | ovarian cancer and other solid tumors | |
Cixutumumab | mab | human | IGF-1 receptor | solid tumors | |
Clazakizumab | mab | humanized | Oryctolagus cuniculus | rheumatoid arthritis | |
Clenoliximab | mab | chimeric | CD4 | rheumatoid arthritis | |
Clivatuzumab tetraxetan | hPAM4-Cide | mab | humanized | MUC1 | pancreatic cancer |
Conatumumab | mab | human | TRAIL-R2 | cancer | |
Concizumab | mab | humanized | TFPI | bleeding | |
Crenezumab | mab | humanized | MABT5102A | Alzheimer's disease | |
CR6261 | mab | human | Influenza A hemagglutinin | infectious disease/influenza A | |
Dacetuzumab | mab | humanized | CD40 | hematologic cancers | |
Daclizumab | Zenapax | mab | humanized | CD25 (α chain of IL-2 receptor) | prevention of organ transplant rejections |
Dalotuzumab | mab | humanized | insulin-like growth factor I receptor | cancer etc. | |
Daratumumab | mab | human | CD38 (cyclic ADP ribose hydrolase) | ? | |
Demcizumab | mab | humanized | DLL4 | cancer | |
Denosumab | Prolia | mab | human | RANKL | osteoporosis, bone metastases etc. |
Detumomab | mab | mouse | B-lymphoma cell | lymphoma | |
Dorlimomab aritox | F(ab')2 | mouse | ? | ? | |
Drozitumab | mab | human | DR5 | cancer etc. | |
Duligotumab | mab | human | HER3 | ? | |
Dupilumab | mab | human | IL4 | atopic diseases | |
Dusigitumab | mab | human | ILGF2 | cancer | |
Ecromeximab | mab | chimeric | GD3 ganglioside | malignant melanoma | |
Eculizumab | Soliris | mab | humanized | C5 | paroxysmal nocturnal hemoglobinuria |
Edobacomab | mab | mouse | endotoxin | sepsis caused by Gram-negative bacteria | |
Edrecolomab | Panorex | mab | mouse | EpCAM | colorectal carcinoma |
Efalizumab | Raptiva | mab | humanized | LFA-1 (CD11a) | psoriasis (blocks T-cell migration) |
Efungumab | Mycograb | scFv | human | Hsp90 | invasive Candida infection |
Elotuzumab | mab | humanized | SLAMF7 | multiple myeloma | |
Elsilimomab | mab | mouse | IL-6 | ? | |
Enavatuzumab | mab | humanized | PDL192 | cancer etc. | |
Enlimomab pegol | mab | mouse | ICAM-1 (CD54) | ? | |
Enokizumab | mab | humanized | MEDI-528 | asthma | |
Enoticumab | mab | human | DLL4 | ? | |
Ensituximab | mab | chimeric | NPC-1C | cancer | |
Epitumomab cituxetan | mab | mouse | episialin | ? | |
Epratuzumab | mab | humanized | CD22 | cancer, SLE | |
Erlizumab | F(ab')2 | humanized | ITGB2 (CD18) | heart attack, stroke, traumatic shock | |
Ertumaxomab | Rexomun | 3funct | rat/mouse hybrid | HER2/neu, CD3 | breast cancer etc. |
Etaracizumab | Abegrin | mab | humanized | integrin αvβ3 | melanoma, prostate cancer, ovarian cancer etc. |
Etrolizumab | mab | humanized | rhuMAb β7 | inflammatory bowel disease | |
Evolocumab | mab | human | PCSK9 | hypocholesterolemia | |
Exbivirumab | mab | human | hepatitis B surface antigen | hepatitis B | |
Fanolesomab | NeutroSpec | mab | mouse | CD15 | appendicitis (diagnosis) |
Faralimomab | mab | mouse | interferon receptor | ? | |
Farletuzumab | mab | humanized | folate receptor 1 | ovarian cancer | |
Fasinumab | mab | human | HNGF | ? | |
FBTA05 | Lymphomun | 3funct | rat/mouse hybrid | CD20 | chronic lymphocytic leukaemia |
Felvizumab | mab | humanized | respiratory syncytial virus | respiratory syncytial virus infection | |
Fezakinumab | mab | human | IL-22 | rheumatoid arthritis, psoriasis | |
Ficlatuzumab | mab | humanized | SCH 900105 | cancer etc. | |
Figitumumab | mab | human | IGF-1 receptor | adrenocortical carcinoma, non-small cell lung carcinoma etc. | |
Flanvotumab | mab | human | glycoprotein 75 | melanoma | |
Fontolizumab | HuZAF | mab | humanized | IFN-γ | Crohn's disease etc. |
Foralumab | mab | human | CD3 epsilon | ? | |
Foravirumab | mab | human | rabies virus glycoprotein | rabies (prophylaxis) | |
Fresolimumab | mab | human | TGF-β | idiopathic pulmonary fibrosis, focal segmental glomerulosclerosis, cancer | |
Fulranumab | mab | human | NGF | pain | |
Futuximab | mab | chimeric | EGFR | ? | |
Galiximab | mab | chimeric | CD80 | B-cell lymphoma | |
Ganitumab | mab | human | IGF-I | cancer | |
Gantenerumab | mab | human | beta amyloid | Alzheimer's disease | |
Gavilimomab | mab | mouse | CD147 (basigin) | graft versus host disease | |
Gemtuzumab ozogamicin | Mylotarg | mab | humanized | CD33 | acute myelogenous leukemia |
Gevokizumab | mab | humanized | IL-1β | diabetes etc. | |
Girentuximab | Rencarex | mab | chimeric | carbonic anhydrase 9 (CA-IX) | clear cell renal cell carcinoma |
Glembatumumab vedotin | mab | human | GPNMB | melanoma, breast cancer | |
Golimumab | Simponi | mab | human | TNF-α | rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis |
Gomiliximab | mab | chimeric | CD23 (IgE receptor) | allergic asthma | |
GS6624 | mab | ? | ? | idiopathic pulmonary fibrosis and solid tumors | |
Ibalizumab | mab | humanized | CD4 | HIV infection | |
Ibritumomab tiuxetan | Zevalin | mab | mouse | CD20 | non-Hodgkin's lymphoma |
Icrucumab | mab | human | VEGFR-1 | cancer etc. | |
Igovomab | Indimacis-125 | F(ab')2 | mouse | CA-125 | ovarian cancer (diagnosis) |
Imciromab | Myoscint | mab | mouse | cardiac myosin | cardiac imaging |
Imgatuzumab | mab | humanized | EGFR | cancer | |
Inclacumab | mab | human | selectin P | ? | |
Indatuximab ravtansine | mab | chimeric | SDC1 | cancer | |
Infliximab | Remicade | mab | chimeric | TNF-α | rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis, Crohn's disease, ulcerative colitis |
Intetumumab | mab | human | CD51 | solid tumors (prostate cancer, melanoma) | |
Inolimomab | mab | mouse | CD25 (α chain of IL-2 receptor) | graft versus host disease | |
Inotuzumab ozogamicin | mab | humanized | CD22 | cancer | |
Ipilimumab | Yervoy | mab | human | CD152 | melanoma |
Iratumumab | mab | human | CD30 (TNFRSF8) | Hodgkin's lymphoma | |
Itolizumab | mab | humanized | CD6 | ? | |
Ixekizumab | mab | humanized | IL-17A | autoimmune diseases | |
Keliximab | mab | chimeric | CD4 | chronic asthma | |
Labetuzumab | CEA-Cide | mab | humanized | CEA | colorectal cancer |
Lampalizumab | mab | humanized | CFD | ? | |
Lebrikizumab | mab | humanized | IL-13 | asthma | |
Lemalesomab | mab | mouse | NCA-90 (granulocyte antigen) | diagnostic agent | |
Lerdelimumab | mab | human | TGF beta 2 | reduction of scarring after glaucoma surgery | |
Lexatumumab | mab | human | TRAIL-R2 | cancer | |
Libivirumab | mab | human | hepatitis B surface antigen | hepatitis B | |
Ligelizumab | mab | humanized | IGHE | ? | |
Lintuzumab | mab | humanized | CD33 | cancer | |
Lirilumab | mab | human | KIR2D | ? | |
Lodelcizumab | mab | humanized | PCSK9 | hypercholesterolemia | |
Lorvotuzumab mertansine | mab | humanized | CD56 | cancer | |
Lucatumumab | mab | human | CD40 | multiple myeloma, non-Hodgkin's lymphoma, Hodgkin's lymphoma | |
Lumiliximab | mab | chimeric | CD23 (IgE receptor) | chronic lymphocytic leukemia | |
Mapatumumab | mab | human | TRAIL-R1 | cancer | |
Maslimomab | ? | mouse | T-cell receptor | ? | |
Mavrilimumab | mab | human | CAM-3001 | rheumatoid arthritis | |
Matuzumab | mab | humanized | EGFR | colorectal, lung and stomach cancer | |
Mepolizumab | Bosatria | mab | humanized | IL-5 | asthma and white blood cell diseases |
Metelimumab | mab | human | TGF beta 1 | systemic scleroderma | |
Milatuzumab | mab | humanized | CD74 | multiple myeloma and other hematological malignancies | |
Minretumomab | mab | mouse | TAG-72 | ? | |
Mitumomab | mab | mouse | GD3 ganglioside | small cell lung carcinoma | |
Mogamulizumab | mab | humanized | CCR4 | cancer | |
Morolimumab | mab | human | Rhesus factor | ? | |
Motavizumab | Numax | mab | humanized | respiratory syncytial virus | respiratory syncytial virus (prevention) |
Moxetumomab pasudotox | mab | mouse | CD22 | cancer | |
Muromonab-CD3 | Orthoclone OKT3 | mab | mouse | CD3 | prevention of organ transplant rejections |
Nacolomab tafenatox | Fab | mouse | C242 antigen | colorectal cancer | |
Namilumab | mab | human | CSF2 | ? | |
Naptumomab estafenatox | Fab | mouse | 5T4 | non-small cell lung carcinoma, renal cell carcinoma | |
Narnatumab | mab | human | RON | cancer | |
Natalizumab | Tysabri | mab | humanized | integrin α4 | multiple sclerosis, Crohn's disease |
Nebacumab | mab | human | endotoxin | sepsis | |
Necitumumab | mab | human | EGFR | non-small cell lung carcinoma | |
Nerelimomab | mab | mouse | TNF-α | ? | |
Nesvacumab | mab | human | angiopoietin 2 | cancer | |
Nimotuzumab | Theracim, Theraloc | mab | humanized | EGFR | squamous cell carcinoma, head and neck cancer, nasopharyngeal cancer, glioma |
Nivolumab | mab | human | IgG4 | cancer | |
Nofetumomab merpentan | Verluma | Fab | mouse | ? | cancer (diagnosis) |
Ocaratuzumab | mab | humanized | CD20 | cancer | |
Ocrelizumab | mab | humanized | CD20 | rheumatoid arthritis, lupus erythematosus etc. | |
Odulimomab | mab | mouse | LFA-1 (CD11a) | prevention of organ transplant rejections, immunological diseases | |
Ofatumumab | Arzerra | mab | human | CD20 | chronic lymphocytic leukemia etc. |
Olaratumab | mab | human | PDGF-R α | cancer | |
Olokizumab | mab | humanized | IL6 | ? | |
Omalizumab | Xolair | mab | humanized | IgE Fc region | allergic asthma |
Onartuzumab | mab | humanized | human scatter factor receptor kinase | cancer | |
Oportuzumab monatox | scFv | humanized | EpCAM | cancer | |
Oregovomab | OvaRex | mab | mouse | CA-125 | ovarian cancer |
Orticumab | mab | human | oxLDL | ? | |
Otelixizumab | mab | chimeric/humanized | CD3 | diabetes mellitus type 1 | |
Oxelumab | mab | human | OX-40 | asthma | |
Ozanezumab | mab | humanized | NOGO-A | ALS and multiple sclerosis | |
Ozoralizumab | mab | humanized | Lama glama | inflammation | |
Pagibaximab | mab | chimeric | lipoteichoic acid | sepsis (Staphylococcus) | |
Palivizumab | Synagis, Abbosynagis | mab | humanized | F protein of respiratory syncytial virus | respiratory syncytial virus (prevention) |
Panitumumab | Vectibix | mab | human | EGFR | colorectal cancer |
Panobacumab | mab | human | Pseudomonas aeruginosa | Pseudomonas aeruginosa infection | |
Parsatuzumab | mab | human | EGFL7 | cancer | |
Pascolizumab | mab | humanized | IL-4 | asthma | |
Pateclizumab | mab | humanized | LTA | TNF | |
Patritumab | mab | human | HER3 | cancer | |
Pemtumomab | Theragyn | ? | mouse | MUC1 | cancer |
Perakizumab | mab | humanized | IL17A | ? | |
Pertuzumab | Omnitarg | mab | humanized | HER2/neu | cancer |
Pexelizumab | scFv | humanized | C5 | reduction of side effects of cardiac surgery | |
Pidilizumab | mab | humanized | PD-1 | cancer and infectious diseases | |
Pinatuzumab vedotin | mab | humanized | CD22 | cancer | |
Pintumomab | mab | mouse | adenocarcinoma antigen | adenocarcinoma (imaging) | |
Placulumab | mab | human | human TNF | ? | |
Polatuzumab vedotin | mab | humanized | CD79B | ? | |
Ponezumab | mab | humanized | human beta-amyloid | Alzheimer's disease | |
Priliximab | mab | chimeric | CD4 | Crohn's disease, multiple sclerosis | |
Pritoxaximab | mab | chimeric | E. coli shiga toxin type-1 | ? | |
Pritumumab | mab | human | vimentin | brain cancer | |
PRO 140 | ? | humanized | CCR5 | HIV infection | |
Quilizumab | mab | humanized | IGHE | ? | |
Racotumomab | mab | mouse | N-glycolylneuraminic acid | cancer | |
Radretumab | mab | human | fibronectin extra domain-B | cancer | |
Rafivirumab | mab | human | rabies virus glycoprotein | rabies (prophylaxis) | |
Ramucirumab | mab | human | VEGFR2 | solid tumors | |
Ranibizumab | Lucentis | Fab | humanized | VEGF-A | macular degeneration (wet form) |
Raxibacumab | mab | human | anthrax toxin, protective antigen | anthrax (prophylaxis and treatment) | |
Regavirumab | mab | human | cytomegalovirus glycoprotein B | cytomegalovirus infection | |
Reslizumab | mab | humanized | IL-5 | inflammations of the airways, skin and gastrointestinal tract | |
Rilotumumab | mab | human | HGF | solid tumors | |
Rituximab | MabThera, Rituxan | mab | chimeric | CD20 | lymphomas, leukemias, some autoimmune disorders |
Robatumumab | mab | human | IGF-1 receptor | cancer | |
Roledumab | mab | human | RHD | ? | |
Romosozumab | mab | humanized | scleroscin | osteoporosis | |
Rontalizumab | mab | humanized | IFN-α | systemic lupus erythematosus | |
Rovelizumab | LeukArrest | mab | humanized | CD11, CD18 | haemorrhagic shock etc. |
Ruplizumab | Antova | mab | humanized | CD154 (CD40L) | rheumatic diseases |
Samalizumab | mab | humanized | CD200 | cancer | |
Sarilumab | mab | human | IL6 | rheumatoid arthritis, ankylosing spondylitis | |
Satumomab pendetide | mab | mouse | TAG-72 | cancer (diagnosis) | |
Secukinumab | mab | human | IL-17A | uveitis, rheumatoid arthritis psoriasis | |
Seribantumab | mab | human | ERBB3 | cancer | |
Setoxaximab | mab | chimeric | E. coli shiga toxin type-1 | ? | |
Sevirumab | ? | human | cytomegalovirus | cytomegalovirus infection | |
Sibrotuzumab | mab | humanized | FAP | cancer | |
Sifalimumab | mab | humanized | IFN-α | SLE, dermatomyositis, polymyositis | |
Siltuximab | mab | chimeric | IL-6 | cancer | |
Simtuzumab | mab | humanized | LOXL2 | ? | |
Siplizumab | mab | humanized | CD2 | psoriasis, graft-versus-host disease (prevention) | |
Sirukumab | mab | human | IL-6 | rheumatoid arthritis | |
Solanezumab | mab | humanized | beta amyloid | Alzheimer's disease | |
Solitomab | mab | mouse | EPCAM | ? | |
Sonepcizumab | ? | humanized | sphingosine-1-phosphate | choroidal and retinal neovascularization | |
Sontuzumab | mab | humanized | episialin | ? | |
Stamulumab | mab | human | myostatin | muscular dystrophy | |
Sulesomab | LeukoScan | Fab' | mouse | NCA-90 (granulocyte antigen) | osteomyelitis (imaging) |
Suvizumab | mab | humanized | HIV-1 | viral infections | |
Tabalumab | mab | human | BAFF | B-cell cancers | |
Tacatuzumab tetraxetan | AFP-Cide | mab | humanized | alpha-fetoprotein | cancer |
Tadocizumab | Fab | humanized | integrin αIIbβ3 | percutaneous coronary intervention | |
Talizumab | mab | humanized | IgE | allergic reaction | |
Tanezumab | mab | humanized | NGF | pain | |
Taplitumomab paptox | mab | mouse | CD19 | cancer | |
Tefibazumab | Aurexis | mab | humanized | clumping factor A | Staphylococcus aureus infection |
Telimomab aritox | Fab | mouse | ? | ? | |
Tenatumomab | mab | mouse | tenascin C | cancer | |
Teneliximab | mab | chimeric | CD40 | ? | |
Teplizumab | mab | humanized | CD3 | diabetes mellitus type 1 | |
Teprotumumab | mab | human | CD221 | hematologic tumors | |
TGN1412 | ? | humanized | CD28 | chronic lymphocytic leukemia, rheumatoid arthritis | |
Ticilimumab (= tremelimumab) | mab | human | CTLA-4 | cancer | |
Tildrakizumab | mab | humanized | IL23 | immunologically mediated inflammatory disorders | |
Tigatuzumab | mab | humanized | TRAIL-R2 | cancer | |
TNX-650 | ? | humanized | IL-13 | Hodgkin's lymphoma | |
Tocilizumab (= atlizumab) | Actemra, RoActemra | mab | humanized | IL-6 receptor | rheumatoid arthritis |
Toralizumab | mab | humanized | CD154 (CD40L) | rheumatoid arthritis, lupus nephritis etc. | |
Tositumomab | Bexxar | ? | mouse | CD20 | follicular lymphoma |
Tralokinumab | mab | human | IL-13 | asthma etc. | |
Trastuzumab | Herceptin | mab | humanized | HER2/neu | breast cancer |
TRBS07 | Ektomab | 3funct | ? | GD2 | melanoma |
Tregalizumab | mab | humanized | CD4 | ? | |
Tremelimumab | mab | human | CTLA-4 | cancer | |
Tucotuzumab celmoleukin | mab | humanized | EpCAM | cancer | |
Tuvirumab | ? | human | hepatitis B virus | chronic hepatitis B | |
Ublituximab | mab | chimeric | MS4A1 | cancer | |
Urelumab | mab | human | 4-1BB | cancer etc. | |
Urtoxazumab | mab | humanized | Escherichia coli | diarrhoea caused by E. coli | |
Ustekinumab | Stelara | mab | human | IL-12, IL-23 | multiple sclerosis, psoriasis, psoriatic arthritis |
Vapaliximab | mab | chimeric | AOC3 (VAP-1) | ? | |
Vatelizumab | mab | humanized | ITGA2 | ? | |
Vedolizumab | mab | humanized | integrin α4β7 | Crohn's disease, ulcerative colitis | |
Veltuzumab | mab | humanized | CD20 | non-Hodgkin's lymphoma | |
Vepalimomab | mab | mouse | AOC3 (VAP-1) | inflammation | |
Vesencumab | mab | human | NRP1 | ? | |
Visilizumab | Nuvion | mab | humanized | CD3 | Crohn's disease, ulcerative colitis |
Volociximab | mab | chimeric | integrin α5β1 | solid tumors | |
Vorsetuzumab mafodotin | mab | humanized | cancer | ||
Votumumab | HumaSPECT | mab | human | tumor antigen CTAA16.88 | colorectal tumors |
Zalutumumab | HuMax-EGFr | mab | human | EGFR | squamous cell carcinoma of the head and neck |
Zanolimumab | HuMax-CD4 | mab | human | CD4 | rheumatoid arthritis, psoriasis, T-cell lymphoma |
Zatuximab | mab | chimeric | HER1 | cancer | |
Ziralimumab | mab | human | CD147 (basigin) | ? | |
Zolimomab aritox | mab | mouse | CD5 | systemic lupus erythematosus, graft-versus-host disease |
Famous quotes containing the words list of and/or list:
“The advice of their elders to young men is very apt to be as unreal as a list of the hundred best books.”
—Oliver Wendell Holmes, Jr. (18411935)
“Loves boat has been shattered against the life of everyday. You and I are quits, and its useless to draw up a list of mutual hurts, sorrows, and pains.”
—Vladimir Mayakovsky (18931930)